Chimeric Therapeutics (CHM) NWR Virtual Healthcare Conference summary

Key announcements and financial updates

• Announced an AUD 3.2 million entitlement offer and previously secured AUD 4 million in non-dilutive funding to support ongoing trials.

• Market cap currently sits just under AUD 10 million, with a focus on maintaining financial stability for clinical progress.

• Multiple clinical catalysts expected in the next 12 months, with a strong leadership and manufacturing team.

Clinical trial progress and results

• Lead asset CHM CDH17 is in phase I/II trials targeting GI cancers, with four patients dosed and no dose-limiting toxicities observed.

• Early clinical data show stable disease in two patients at day 28 and day 60, including a durable response in a rapidly progressing neuroendocrine tumor.

• Manufacturing process has achieved five successful GMP runs, with a sixth underway and three active clinical sites in the U.S.

• Off-the-shelf CORE-NK platform has shown a complete response in a patient with ongoing remission over four years.

Strategic priorities and future plans

• CHM CDH17 is prioritized for its commercial potential in a $25 billion U.S. market, especially for younger bowel cancer patients.

• CORE-NK is advancing as the first cell therapy tested frontline in blood cancer, with rapid recruitment and expansion in AML trials.

• Plans to complete phase I and move directly into phase II for CHM CDH17, aiming for market entry at the end of phase II.

• Exploring partnerships with major pharma companies to fund phase II and beyond, leveraging recent clinical results.